BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $14,225.60 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 523 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $27.20, for a total transaction of $14,225.60. Following the completion of the sale, the executive vice president now directly owns 283,919 shares of the company’s stock, valued at approximately $7,722,596.80. The trade was a 0.18 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

BioLife Solutions Stock Up 1.1 %

Shares of NASDAQ BLFS opened at $27.47 on Monday. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -25.92 and a beta of 1.88. BioLife Solutions, Inc. has a 12 month low of $11.91 and a 12 month high of $28.88. The stock has a 50-day moving average price of $24.23 and a two-hundred day moving average price of $23.24.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC acquired a new position in BioLife Solutions during the third quarter worth about $28,000. 1620 Investment Advisors Inc. acquired a new position in shares of BioLife Solutions in the second quarter valued at approximately $35,000. Isthmus Partners LLC increased its stake in shares of BioLife Solutions by 34.4% in the second quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 42,265 shares during the period. Quest Partners LLC acquired a new position in shares of BioLife Solutions in the third quarter valued at approximately $57,000. Finally, GAMMA Investing LLC increased its stake in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 748 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BLFS shares. Northland Securities upped their price objective on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. TD Cowen upped their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. HC Wainwright cut their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Finally, Craig Hallum upped their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $27.50.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.